Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN953777 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-NudC Domain Containing 1 (NUDCD1) (AA 193-223), (Middle Region) antibody
- Antibody type
- Polyclonal
- Description
- Protein A column, followed by peptide affinity purification
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 193-223, Middle Region
- Vial size
- 0.4 mL
- Storage
- Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells.
Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity.
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
Wang Q, Li M, Wang Y, Zhang Y, Jin S, Xie G, Liu Z, Wang S, Zhang H, Shen L, Ge H
Cancer letters 2008 Sep 28;269(1):127-38
Cancer letters 2008 Sep 28;269(1):127-38
Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity.
Jin S, Wang Y, Zhang Y, Zhang HZ, Wang SJ, Tang JQ, Chen HJ, Ge HL
Cancer science 2008 Aug;99(8):1670-8
Cancer science 2008 Aug;99(8):1670-8
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
Yan Y, Phan L, Yang F, Talpaz M, Yang Y, Xiong Z, Ng B, Timchenko NA, Wu CJ, Ritz J, Wang H, Yang XF
Journal of immunology (Baltimore, Md. : 1950) 2004 Jan 1;172(1):651-60
Journal of immunology (Baltimore, Md. : 1950) 2004 Jan 1;172(1):651-60
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
Yang XF, Wu CJ, McLaughlin S, Chillemi A, Wang KS, Canning C, Alyea EP, Kantoff P, Soiffer RJ, Dranoff G, Ritz J
Proceedings of the National Academy of Sciences of the United States of America 2001 Jun 19;98(13):7492-7
Proceedings of the National Academy of Sciences of the United States of America 2001 Jun 19;98(13):7492-7
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
